Foscenvivint (ICG-001)

目录号:S2662

仅限科研使用

Foscenvivint (ICG-001)拮抗Wnt/β-catenin/TCF介导的转录,并特异性结合到启动子结合蛋白(CBP),IC50为3 μM,但不能结合到相关的转录共激活因子p300上。ICG-001 可诱导凋亡。

Foscenvivint (ICG-001) Chemical Structure

CAS: 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry)

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1377.83 现货
RMB 976.49 现货
RMB 3835.04 现货
RMB 10401.3 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Foscenvivint (ICG-001)发表文献162篇:

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述 Foscenvivint (ICG-001)拮抗Wnt/β-catenin/TCF介导的转录,并特异性结合到启动子结合蛋白(CBP),IC50为3 μM,但不能结合到相关的转录共激活因子p300上。ICG-001 可诱导凋亡。
靶点
CBP [1]
(Cell-free assay)
3 μM
体外研究

ICG-001 作用于TOPFLASH 时,IC50为3 μM,而对含突变TCF位点的相关报告基因结构, FOPFLASH没有作用效果。使用25μM ICG-001处理SW480 细胞8小时后,降低Survivin和 Cyclin D1 RNA和蛋白的稳定水平,这两者都可通过β-catenin上调。ICG-001 作用于转化细胞而不是正常结肠细胞,选择性诱导凋亡,降低结肠癌细胞生长。[1] ICG-001作用于presenilin-1突变细胞,可表型营救正常神经生长因子(NGF)诱导的神经元分化和神经轴突生长,强调TCF/β-catenin 信号通路在神经轴突生长和神经元分化中的重要性。[2] 最新研究显示 5μM ICG-001作用于MCF7细胞,抑制leptin诱导的EMT, 入侵和肿瘤干细胞球形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SH-SY5Y M4fjOmFxd3C2b4Ppd{BCe3OjeR?= NXfOVHAxPTEEoN88cS=> M{e5TVI1yqCq MmnNSG1UVw>? MnH1Zoxw[2u|wrD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZibXXsZZRwdmmwIHHnZYlve3RiUILQJEgyODckgKOxNlYqNWmwZIXj[YQh[XCxcITveIlkKHOrZ37hcJM> MlLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NUGwNlgoRjJ3MkWxNFI5RC:jPh?=
AsPC-1 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXkNU0zOCEQvF2= MX:yM|QwPiCm M3O1SolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHTrcoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4Nlk3OCd-MkWwPFI6PjB:L3G+
MiaPaCa-2 NX3ET3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzTNU0zOCEQvF2= M4PsZ|IwPC94IHS= NHG2cGVqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEXZPIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC4Nlk3OCd-MkWwPFI6PjB:L3G+
PANC-1 NWnVSm84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxMVIxKM7:TR?= MYGyM|QwPiCm M2XKd4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyOEK5OlAoRjJ3MEiyPVYxRC:jPh?=
L3.6pl M{W0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHteHEyNTJyIN88US=> MUeyM|QwPiCm NXS2OpF[cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXTpPWh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPFI6PjBpPkK1NFgzQTZyPD;hQi=>
SH-SY5Y NXOzPJh4SXCxcITvd4l{KEG|c3H5 M2jlN|ExKM7:TR?= MVuyOEBp NUXp[YF1cW6qaXLpeJMhfGinIH7leZJweHKxdHXjeIl3\SCnZn\lZ5R{KG:oIHj5dI95cWFiYXfhbY5{fCCScmCgLFExPi1zMk[pMY1m\GmjdHXkJI5mfXKxbnHsJINmdGxiZHXheIg> NGX0T3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mwNFU3Pid-MkO5NFA2PjZ:L3G+
HKC-8  MkTySpVv[3Srb36gRZN{[Xl? M{DOXFExyqEEtV2= M2DYSVI1KGh? NFG1dW1i[m:uaYPo[ZPDqM7{LXPheIVvcW8kgKPt[YRq[XSnZDDSRXMhcW6mdXP0bY9v MlvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUKxOlYoRjJ3MEGyNVY3RC:jPh?=
HK-2  MXzGeY5kfGmxbjDBd5NigQ>? NHvWTXkyOCEEtV2= NGP5TJQ{KGh? NYq0S3FLemWmdXPl[EB1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxMEDPuS2VTVGsJIFv\CCFVFfGJIFnfGW{IITy[YF1dWWwdDD3bZRpKEiKRR?= NHnBRW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[5NFk6Pyd-MkO2PVA6QTd:L3G+
HepT1 NIH3fmdCeG:ydH;zbZMhSXO|YYm= M1LZWVAuOTBywrFOwG0> NGT6O5IzPCCq Mnr3TWM2OD1|NNMg{txO MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4NkexPEc,OjN{Nk[3NVg9N2F-
HuH6 MX7BdI9xfG:|aYOgRZN{[Xl? MWqwMVExOMLizszN MWOyOEBp MXTJR|UxRTN7wrFOwG0> Moq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nk[3NVgoRjJ|Mk[2O|E5RC:jPh?=
MCF7 Ml;USpVv[3Srb36gRZN{[Xl? NVzTUJFqPSEQvH5CpC=> NUjOeHk1cW6qaXLpeJMhdGWydHnuMY1m\GmjdHXkJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIGPuZYltNCCVbIXnMEBidmRiWnXiNi=> Mlu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{CzOVkoRjJ{MkewN|U6RC:jPh?=
RLE-6TN  M4n2W2Z2dmO2aX;uJGF{e2G7 NX7hOFB4Oi53L{WvO{42KM7:TR?= NHnmOW01QCCq NUDXSo4xcW6qaXLpeJMhXEeILd8yNU1qdmS3Y3XkJO6yNVOPQTDpcoR2[3Srb36gZY5lKEWPVB?= M1G0UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkSxOFc5Lz5{MkK0NVQ4QDxxYU6=
HKC-8 M3T2bGZ2dmO2aX;uJGF{e2G7 NGL6R2E2NzFyL{KwJO69VQ>? NVvxPGJJPDhiaB?= MmCwZoxw[2u|IN8yMYNifGWwaX6t[JJqfmWwIHflcoUh\XiycnXzd4lwdg>? M{TVUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEG2PVM4Lz5{MUixOlk{PzxxYU6=
SW480 NFTHWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGyMVExOCEQvF2= NGm4dm5KSzVyPUWuPOKyOC54ODFOwG0> M1\ucVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3N{iyNVM5Lz5zNUe4NlE{QDxxYU6=
SW480 MUXGeY5kfGmxbjDhd5NigQ>? NVfW[3ZLUW6qaXLpeIlwdiCxZjDDRnAh[mmwZHnu[{B1dyCkZYThMYNie2WrbjDpckBpfW2jbjDTW|Q5OCClZXzsd{BjgSCrbX31co9jdG:2IHHuZYx6e2m|LDDJR|UxKD1iMT6zJO69VS5? NIq5cHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNlA3OCd-MkOyN|IxPjB:L3G+
A549 MnHlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MX23NkBpenN? M{X2SmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iNj6xJO69VS5? MmO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUC0PFkoRjJ2OUWwOFg6RC:jPh?=
HepG2 NEjhdmhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{jKS|czKGi{cx?= MlLBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMUKuO{DPxE1w MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
LoVo NVm2NFlSSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M{jBU|czKGi{cx?= NVLHO5BtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCxOU43KM7:TT6= Mn\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUC0PFkoRjJ2OUWwOFg6RC:jPh?=
HT-29 MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MnfzO|IhcHK| NFTHXYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGdKPTBiPTCxO{4zKM7:TT6= NF7Be4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NFQ5QSd-MkS5OVA1QDl:L3G+
HT29 M3;BNmZ2dmO2aX;uJIF{e2G7 NFPROFEzPCCqcoO= NGjRVI1KdmirYnn0bY9vKG:oIGfueEB{cWewYXzpcochcW5iaIXtZY4hUFR{OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGKndHGtZ4F1\W6rbj3t[YRq[XSnZDDUZ4YwVGWoIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjZoTldkAzPCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZkhemWuYYTpeoUhfG9iY3;ueJJwdCxiSVO1NEA:KDF6Lkeg{txONg>? M1LTc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUWwOFg6Lz5{NEm1NFQ5QTxxYU6=
TC32 MnXHdWhVWyCjc4PhfS=> NHTIZ4ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= Mn7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 MUPxTHRUKGG|c3H5 MlGxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NVfMcIJSeUiWUzDhd5NigQ>? M{D0OZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NGq4NnFyUFSVIHHzd4F6 M3WwNJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MV3xTHRUKGG|c3H5 MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M3nne|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M1faWJFJXFNiYYPzZZk> MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NYizZYFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 MmrldWhVWyCjc4PhfS=> NF\0N3FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz MlfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MYTxTHRUKGG|c3H5 NV\nbYc2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NXz1bWxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NX3p[ZMzeUiWUzDhd5NigQ>? NHviOItyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NVfxT2ZKeUiWUzDhd5NigQ>? NYOySm5[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> M1fKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MnSydWhVWyCjc4PhfS=> M1PRSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NVXiTnNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 NWTEfHp6eUiWUzDhd5NigQ>? NH;XS3ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LoVo MYTDfZRwfG:6aXPpeJkh[XO|YYm= NEO1[lYyOCC3TR?= MX:3NkBpenN? NUnjN285S3m2b4TvfIlkcXS7IHHnZYlve3RiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxtcW6pIHTldIVv\GWwdDDoeY1idiCOb2\vJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFExKHWPIHHmeIVzKDd{IHjyd{BjgSCDVGDsbZRmKGG|c3H5 MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyN|EzOTN7Lze+R4hGVUKOPD;hQi=>
NCI-H1703 MVHGeY5kfGmxbjDhd5NigQ>? MnHkNVAhfU1? M3fYfFI1KGi{cx?= M1XxeWlvcGmkaYTpc44hd2ZiVF7JT{BqdiCqdX3hckBPS0lvSEG3NFMh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDs[Y51cX[rcnHsJJZm[3SxcjC3WGZRKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBIW0t|IHnubIljcXSxcjDYJIFkfGm4YYTl[EBVVkmNLX3l[IlifGWmIGfueE9VS0ZxYnX0ZU1k[XSnbnnuMYRmeGWwZHXueEB1emGwc3PybZB1cW:wIHH0JFExKHWPIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHHzd4F6 M{\kflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI{OTJzM{mvK|5EcEWPQly8M4E,
HCT116 MlH5R5l1d3SxeHnjbZR6KGG|c3H5 MkPRNVAhfU1? MYG3NkBpenN? NEPsRnJEgXSxdH;4bYNqfHliYXfhbY5{fCCZboSvZoV1[S2lYYTlcolvKHOrZ37hcIxqdmdiZHXw[Y5l\W62IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAyOCC3TTDh[pRmeiB5MjDodpMh[nliQWTQcIl1\SCjc4PhfS=> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyN|EzOTN7Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Western blot CCNB1 / Cyclin D1 ABC / Beta-catenin / E-cadherin / N-cadherin / MMP-9 / c-MYC / Actin / Histone H3 beta-catenin / F-actin pβ-catenin SOX-2 / CD44 / Survivin / EGFR / FOXM1 / EZH2 / Vimentin 28893318 29986466 25897700
体内研究 ICG-001 水溶性类似物处理9周,降低42%结肠和小肠息肉的形成,和非甾体类抗炎试剂Sulindac效果类似,Sulindac是一贯治疗这种疾病模型的药物。在整个的处理期间观察不到明显的毒性。类似物按150 mg/kg 剂量静脉注射处理SW620裸鼠肿瘤衰退移植瘤模型,处理19天,显著降低肿瘤体积,没有死亡,体重也没有降低。[1] ICG-001 每天按5 mg/kg剂量处理小鼠,显著抑制beta-catenin信号,且降低 Bleomycin诱导的肺纤维化,同时保护上皮细胞。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
  • 双重-荧光素酶报告基因实验:

    双重-荧光素酶报告基因实验系统提供形成双重报告基因实验的有效方法。在DLR™ 实验中, 顺序测量萤火虫型和花虫型荧光素酶活性。加入荧光素酶实验试剂 II (LAR II),获得“辉光型”发光信号,测量萤火虫型荧光素酶报告基因。定量测量萤火虫荧光素酶后, 淬灭反应,同时在相同试管中加入Stop & Glo® 试剂开始花虫型荧光素酶反应。通过花型荧光素酶,Stop & Glo® 试剂也产生“光辉型”信号,在测量过程中缓慢降解。在 DLR™ 实验系统中, 两种报告基因都使用亚原子(<10-18) 敏感性进行线性分析,在实验宿主细胞中都没有内在活性。而且, DLR™ 实验的集成格式可以使在转化细胞或无细胞转录/翻译反应中快速测量报告基因。

细胞实验:[1]
  • Cell lines: Human colon carcinoma cell lines SW480, SW620, and HCT116, normal colonic epithelial cell line CCD-841Co
  • Concentrations: ~25 μM
  • Incubation Time: 24 hours
  • Method: 1. Prior to starting the assay, prepare the Apo-ONE Caspase-3/7 Reagent, and mix thoroughly. 2. For best results, empirical determination of the optimal cell number, apoptosis induction treatment and incubation period for the cell culture system may be necessary. 3. Use identical cell numbers and volumes for the assay and the negative control samples. 4. Do not mix Apo-ONE Caspase-3/7 Reagent and samples by manual pipetting. Mixing in this manner is unnecessary and may create bubbles that interfere with fluorescence readings or cross-contaminate the samples. Gentle mixing may be performed using a plate shaker. 5. Total incubation time for the assay depends upon the amount of caspase- 3/7 present in the sample. 6. The Apo-ONE Caspase-3/7 Reagent is formulated to mediate cellular lysis and support optimal caspase-3/7 activity. In rare instances, the reagent does not affect complete lysis of cultured cells. In such cases, lysis is enhanced by a freeze-thaw cycle. For best results, freeze at -70 °C, then thaw at room temperature. After equilibration, mix to homogeneity and incubate until measurable fluorescence is achieved
动物实验: [1]
  • Animal Models: 7周大的雄性C57BL/6J-Apc Min/+小鼠
  • Dosages: 300 mg/kg
  • Administration: ICG-001水溶性类似物每天口服处理,持续9周

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+50% PEG 300+5% Tween 80+ddH2O

5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 548.63
化学式

C33H32N4O4

CAS号 780757-88-2 (relative stereochemistry); 847591-62-2 (absolute stereochemistry)
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
If the compound is stored in DMSO at -80, how long would it be stable? For cell culture, how long should I change for the fresh medium with ICG-001?

回答:
The product in DMSO solution can be stored at 4 degree for 1 week and -20 degree for 1 month. The best storage condition is solid powder, even at -80 the solution is not stable enough for long term storage. For cell culture, you need change medium every 48h.

Tags: buy Foscenvivint (ICG-001) | Foscenvivint (ICG-001) supplier | purchase Foscenvivint (ICG-001) | Foscenvivint (ICG-001) cost | Foscenvivint (ICG-001) manufacturer | order Foscenvivint (ICG-001) | Foscenvivint (ICG-001) distributor